Matrix Aging and Aneurysm
VIMANE
Role of Molecular Aging of Matrix Proteins of the Vessel Wall in the Aneurysm Pathology
1 other identifier
interventional
24
1 country
1
Brief Summary
During their biological life, proteins undergo molecular aging due to many non-enzymatic post-translational modifications that alter their structural and functional properties. These reactions concern all proteins but especially tissue proteins (whose half-life in the organism can be several decades) and lead to the formation of complex products called PTMDPs ("post-translational modification derived products"). Molecular aging is responsible for the alteration of protein properties which may cause changes in mechanical properties of tissues during aging and pathologies. However, the involvement of these processes in vivo remains unclear, particularly in the aneurysmal pathology. So, the aim of this study is to determine whether the molecular aging of matrix proteins within the vessel wall may participate in the development of aortic aneurysm.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2015
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2015
CompletedFirst Submitted
Initial submission to the registry
May 20, 2016
CompletedFirst Posted
Study publicly available on registry
May 27, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 22, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
November 22, 2016
CompletedJanuary 21, 2026
April 1, 2018
1.8 years
May 20, 2016
January 19, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
blood collection
at the same time of surgery
measurement of skin autofluorescence with AGE-reader (Diagnoptics®)
at the same time of surgery
Study Arms (2)
aneurysm diameter of below 75 mm
EXPERIMENTALaneurysm diameter above 75 mm
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Patients with aneurysm of the infrarenal abdominal aorta requiring surgical care by open surgery.
- Patients older than 18 years.
- Patients who agreed to participate in the study.
You may not qualify if:
- Patients with aneurysm of the abdominal infrarenal aorta due to trauma or infection.
- Patients who have already received surgery for an aneurysm of abdominal aorta.
- Patients who are protected by law.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- CHU de Reimslead
Study Sites (1)
Chu Reims
Reims, 51092, France
Related Publications (1)
Doue M, Marques G, Okwieka A, Gorisse L, Pietrement C, Gillery P, Jaisson S. Accumulation of Carbamylation-Derived Products in Aneurysmal Aorta. J Vasc Res. 2024;61(2):51-58. doi: 10.1159/000534613. Epub 2024 Jan 19.
PMID: 38246153BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 20, 2016
First Posted
May 27, 2016
Study Start
February 1, 2015
Primary Completion
November 22, 2016
Study Completion
November 22, 2016
Last Updated
January 21, 2026
Record last verified: 2018-04